Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | inglese |
| Pubblicazione: |
2019
|
| Accesso online: | https://doi.org/10.1038/s41375-019-0384-1 https://www.nature.com/articles/s41375-019-0384-1.pdf |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|